Showing 4851-4860 of 20470 results for "".
- Findings on Synthetic Hypericin in Cutaneous T-Cell Lymphomahttps://reachmd.com/news/hypericin-cutaneous-t-cell-lymphoma/2486557/Key Takeaways: In cutaneous T-cell lymphoma, synthetic hypericin was reported to show higher 12-week treatment success and greater cumulative mCAILS improvement than mechlorethamine. The authors said the difference was not statistically significant, ci
- Study: No Meaningful Link Between AD and Adolescent Academic Performancehttps://reachmd.com/news/study-no-meaningful-link-between-ad-and-adolescent-academic-performance/2486567/Atopic dermatitis (AD) was not found to impair academic performance in adolscent patients, according to results from a new analysis of two large European cohorts. Researchers looked at two large, population-based cohort studi
- Allergan Aesthetics Launches Fourth Year of The Confidence Collectivehttps://reachmd.com/news/allergan-aesthetics-launches-fourth-year-of-the-confidence-collective/2486549/Allergan Aesthetics, an AbbVie company, has opened applications for the fourth year of The Confidence Collective, a BOTOX® Cosmetic-branded initiative focused on supporting women entrepreneurs, according to company-provided materials. The application window is open through April 29, 20
- Preclinical Targeting of a GIT1–MAT2B Scaffold in Colon and Liver Cancerhttps://reachmd.com/news/preclinical-targeting-of-a-git1mat2b-scaffold-in-colon-and-liver-cancer/2486539/Key takeaways: Study identifies a GIT1–MAT2B scaffold that supports tumor signaling in colorectal and liver cancer models Small molecule C3 disrupts this interaction by targeting GIT1 Preclinical results show reduced proliferation, increased c
- Fortitude Announces T‑Cell Bispecific Program for Axial Spondyloarthritishttps://reachmd.com/news/fortitude-announces-tcell-bispecific-program-for-axial-spondyloarthritis/2486540/Key points: Fortitude Biomedicines introduced a preclinical bispecific antibody targeting T-cell signaling in axial spondyloarthritis Company-reported animal data suggest selective and durable suppression of disease-associated T-cell activity
- Phase 2 Readouts: Lunsekimig Met Endpoints in Asthma and CRSwNPhttps://reachmd.com/news/phase-2-readouts-lunsekimig-met-endpoints-in-asthma-and-crswnp/2486541/Key points: Lunsekimig met primary and key secondary endpoints in Phase 2 studies in asthma and CRSwNP The therapy targets both TSLP and IL-13 via a bispecific Nanobody® design An exploratory Phase 2 study in atopic dermatitis did not meet its
- Paper: AI Gains Ground in Cosmetic Dermatology Workflowshttps://reachmd.com/news/paper-ai-gains-ground-in-cosmetic-dermatology-workflows/2486551/A recent review in Dermatology and Therapy assessed the growing use of artificial intelligence (AI) across aesthetic dermatology, with the authors reporting increased adoption and highlighting its use in many aspects of prac
- MedStar Union Memorial Tops 1,000 Robotic Spine Procedureshttps://reachmd.com/news/medstar-union-memorial-tops-1000-robotic-spine-procedures/2486543/Key points: MedStar Union Memorial Hospital reported completing 1,000 robotic spine procedures Robotic-assisted surgery is used to improve precision, planning, and implant placement The program reflects years of investment in robotic and navig
- FDA Grants De Novo Classification to neuropacs, an AI MRI Diagnostic Aidhttps://reachmd.com/news/fda-grants-de-novo-classification-to-neuropacs-an-ai-mri-diagnostic-aid/2486545/Key points: FDA granted De Novo classification to neuropacs™, an AI-based MRI diagnostic aid for Parkinsonian syndromes The software analyzes diffusion MRI to help differentiate MSA and PSP from Parkinson’s disease It is intended as a suppleme
- Prediction Model Suggests Reduced Need for Laryngoscopy in Pemphigus Vulgarishttps://reachmd.com/news/model-suggests-reduced-need-for-laryngoscopy-in-pemphigus-vulgaris/2486535/A new proposed clinical prediction model may identify low-risk patients who can safely defer laryngoscopy, reducing unnecessary procedures. Researchers for the retrospective cohort study from a tertiary dermatology center eval